AbbVie, Genmab Need Further Follow Up on Trial for Follicular Lymphoma Treatment
By Paul Ziobro
AbbVie and Genmab said Tuesday that a clinical trial for a bispecific antibody to treat a form of non-Hodgkin's lymphoma would need further follow up, even after it saw positive topline results.
The Epcore NHL-1 trial is evaluating the safety and preliminary efficacy of epcoritamab, an investigational T-cell engaging bispecific antibody administered subcutaneously, in patients with follicular lymphoma.
The companies said topline results showed an overall response rate that exceeded the protocol prespecified threshold for efficacy, while the observed median duration of response wasn't reached, which requires a longer follow up period.
AbbVie and Genmab said they would engage global regulatory authorities to discuss next steps.
"We are encouraged by these topline results, which further support the clinical profile of epcoritamab as a potential therapeutic option for patients with relapsed or refractory follicular lymphoma," said Dr. Mariana Cota Stirner, AbbVie's therapeutic area head for hematology.
Write to Paul Ziobro at paul.ziobro@wsj.com
(END) Dow Jones Newswires
June 27, 2023 19:33 ET (23:33 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits
-
Novo Nordisk Earnings: Raised Fair Value Estimate Still a Contrast to Market Overenthusiasm
-
After Earnings, Is Verizon Stock a Buy, a Sell, or Fairly Valued?
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
How to Invest Like Warren Buffett
-
Cognizant Earnings: Improved Profitability Buttresses Results as Customer Spending Remains Muted
-
10 Top-Performing Dividend Stocks of the Month